Simulations Plus Unveils DILIsym 11: Enhancing Drug-Induced Liver Injury Prediction for Pediatric Patients

Reuters

05-15

<a href="https://laohu8.com/S/SLP">Simulations Plus</a> Unveils DILIsym 11: Enhancing Drug-Induced Liver Injury Prediction for Pediatric Patients

Simulations Plus, Inc. has announced the release of DILIsym® 11, the latest version of its quantitative systems toxicology $(QST.AU)$ software platform, aimed at predicting drug-induced liver injury (DILI). This version introduces new features including pediatric representation, allowing for improved predictions of liver safety in children. Additionally, it offers a new T-cell model to enhance understanding of CD8+ T-cell mediated hepatocellular injury, as well as improved modeling of bile acid and cholestatic liver injury, and updated antioxidant adaptation mechanisms. This advancement is expected to aid in developing safer and more effective therapies, particularly for vulnerable pediatric populations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250515394456) on May 15, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535984170"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535984170\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535984170?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 19:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535984170","market":"nz","top_or_hot":-1,"title":"Simulations Plus Unveils DILIsym 11: Enhancing Drug-Induced Liver Injury Prediction for Pediatric Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLP\">Simulations Plus</a> Unveils DILIsym 11: Enhancing Drug-Induced Liver Injury Prediction for Pediatric Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Simulations Plus, Inc. has announced the release of DILIsym® 11, the latest version of its quantitative systems toxicology <a href=\"https://laohu8.com/S/QST.AU\">$(QST.AU)$</a> software platform, aimed at predicting drug-induced liver injury (DILI). This version introduces new features including pediatric representation, allowing for improved predictions of liver safety in children. Additionally, it offers a new T-cell model to enhance understanding of CD8+ T-cell mediated hepatocellular injury, as well as improved modeling of bile acid and cholestatic liver injury, and updated antioxidant adaptation mechanisms. This advancement is expected to aid in developing safer and more effective therapies, particularly for vulnerable pediatric populations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250515394456) on May 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simulations Plus Unveils DILIsym 11: Enhancing Drug-Induced Liver Injury Prediction for Pediatric Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimulations Plus Unveils DILIsym 11: Enhancing Drug-Induced Liver Injury Prediction for Pediatric Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-15 19:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLP\">Simulations Plus</a> Unveils DILIsym 11: Enhancing Drug-Induced Liver Injury Prediction for Pediatric Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Simulations Plus, Inc. has announced the release of DILIsym® 11, the latest version of its quantitative systems toxicology <a href=\"https://laohu8.com/S/QST.AU\">$(QST.AU)$</a> software platform, aimed at predicting drug-induced liver injury (DILI). This version introduces new features including pediatric representation, allowing for improved predictions of liver safety in children. Additionally, it offers a new T-cell model to enhance understanding of CD8+ T-cell mediated hepatocellular injury, as well as improved modeling of bile acid and cholestatic liver injury, and updated antioxidant adaptation mechanisms. This advancement is expected to aid in developing safer and more effective therapies, particularly for vulnerable pediatric populations.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250515394456) on May 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL35C20l:1","article_id":"2535984170","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535984170","pubTimestamp":1747309818,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Simulations Plus, Inc. has announced the release of DILIsym 11, the latest version of its quantitative systems toxicology  software platform, aimed at predicting drug-induced liver injury . This version introduces new features including pediatric representation, allowing for improved predictions of liver safety in children. Additionally, it offers a new T-cell model to enhance understanding of CD8+ T-cell mediated hepatocellular injury, as well as improved modeling of bile acid and cholestatic liver injury, and updated antioxidant adaptation mechanisms. This advancement is expected to aid in developing safer and more effective therapies, particularly for vulnerable pediatric populations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. S","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Simulations Plus推出DILIsym 11：增强儿科患者药物性肝损伤预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLP":0.9},"content_text":"Simulations Plus Unveils DILIsym 11: Enhancing Drug-Induced Liver Injury Prediction for Pediatric Patients\n    \n\n        Simulations Plus, Inc. has announced the release of DILIsym® 11, the latest version of its quantitative systems toxicology $(QST.AU)$ software platform, aimed at predicting drug-induced liver injury (DILI). This version introduces new features including pediatric representation, allowing for improved predictions of liver safety in children. Additionally, it offers a new T-cell model to enhance understanding of CD8+ T-cell mediated hepatocellular injury, as well as improved modeling of bile acid and cholestatic liver injury, and updated antioxidant adaptation mechanisms. This advancement is expected to aid in developing safer and more effective therapies, particularly for vulnerable pediatric populations.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250515394456) on May 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}